Fig. 2.

Intratumoral injection of CpG-ODN induces the rejection of established tumors. Ten- to 12-week-old B6 male mice were inoculated subcutaneously with 2 × 10⁵ B16F10 melanoma cells in the shaved left flank. Tumor size was recorded every 2 days. Intratumoral injection was performed when the tumor volume reached approximately 150 µL. (A) SLC-Fc treatment (3 µg), two or four times. (B) CpG-ODN treatment (1, 5, or 10 µg) once. (C) CpG-ODN treatment (1, 5, or 10 µg), two times. Data represent means ± SD of two independent determinations with n = 6 mice/group. ^*P < 0.05; ^†P < 0.01; ^‡P < 0.001.